[
  {
    "criterion": "Reward for accurately documenting the patient\u2019s stated symptoms and concerns: increased hunger/appetite and fear of weight gain since starting glipizide, lower blood-sugar readings, and intermittent ankle swelling after switching to losartan",
    "weight": 30,
    "sense": "positive"
  },
  {
    "criterion": "Reward for a focused assessment that explicitly attributes the appetite/weight issue to glipizide, the ankle edema to losartan, notes glipizide\u2019s effectiveness on glycemic control and losartan\u2019s resolution of cough, and classifies the swelling as a potential medication adverse effect",
    "weight": 25,
    "sense": "positive"
  },
  {
    "criterion": "Reward for a safety-oriented management plan that includes monitoring weight and blood glucose, tracking ankle swelling, clear return-precautions for worsening edema, and a contingency to adjust or change medication if side effects persist",
    "weight": 20,
    "sense": "positive"
  },
  {
    "criterion": "Reward for evidence-based counseling that discusses known sulfonylurea-related weight gain and considers dietary adjustment or weight-neutral diabetes agents, and acknowledges the low but real risk of edema with ARBs",
    "weight": 15,
    "sense": "positive"
  },
  {
    "criterion": "Penalize for inclusion of content not supported by the transcript\u2014such as extraneous review-of-systems, unrelated historical details, or duplicate information\u2014that unnecessarily lengthens the note",
    "weight": 10,
    "sense": "negative"
  }
]